KR20180067683A - 피리미딘 조성물, 그의 초순수한 조성물 및 염, 그의 제조 방법, 및 히스타민 h4 수용체 (h4) 매개 질환 및 상태를 치료하기 위한 그의 사용 방법 - Google Patents

피리미딘 조성물, 그의 초순수한 조성물 및 염, 그의 제조 방법, 및 히스타민 h4 수용체 (h4) 매개 질환 및 상태를 치료하기 위한 그의 사용 방법 Download PDF

Info

Publication number
KR20180067683A
KR20180067683A KR1020187014495A KR20187014495A KR20180067683A KR 20180067683 A KR20180067683 A KR 20180067683A KR 1020187014495 A KR1020187014495 A KR 1020187014495A KR 20187014495 A KR20187014495 A KR 20187014495A KR 20180067683 A KR20180067683 A KR 20180067683A
Authority
KR
South Korea
Prior art keywords
composition
pyrimidine
dosage form
pharmaceutical composition
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187014495A
Other languages
English (en)
Korean (ko)
Inventor
지지안 주
헬렌 바커
마이클 예든
와이 리우
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20180067683A publication Critical patent/KR20180067683A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187014495A 2015-10-26 2016-10-25 피리미딘 조성물, 그의 초순수한 조성물 및 염, 그의 제조 방법, 및 히스타민 h4 수용체 (h4) 매개 질환 및 상태를 치료하기 위한 그의 사용 방법 Withdrawn KR20180067683A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US62/246,482 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US62/329,091 2016-04-28
US201662359066P 2016-07-06 2016-07-06
US62/359,066 2016-07-06
PCT/EP2016/075708 WO2017072131A1 (en) 2015-10-26 2016-10-25 Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions

Publications (1)

Publication Number Publication Date
KR20180067683A true KR20180067683A (ko) 2018-06-20

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187014495A Withdrawn KR20180067683A (ko) 2015-10-26 2016-10-25 피리미딘 조성물, 그의 초순수한 조성물 및 염, 그의 제조 방법, 및 히스타민 h4 수용체 (h4) 매개 질환 및 상태를 치료하기 위한 그의 사용 방법

Country Status (21)

Country Link
US (2) US20170158671A1 (enExample)
EP (1) EP3368528A1 (enExample)
JP (1) JP2018531288A (enExample)
KR (1) KR20180067683A (enExample)
CN (1) CN108602801A (enExample)
AU (2) AU2016344627B9 (enExample)
BR (1) BR112018007765A2 (enExample)
CA (1) CA3001636A1 (enExample)
CL (1) CL2018001092A1 (enExample)
CO (1) CO2018004323A2 (enExample)
EC (1) ECSP18038867A (enExample)
HK (1) HK1252050A1 (enExample)
IL (1) IL258813A (enExample)
MX (1) MX2018005140A (enExample)
PE (1) PE20181364A1 (enExample)
PH (1) PH12018500822A1 (enExample)
RU (1) RU2018119104A (enExample)
SG (1) SG11201802676QA (enExample)
TW (1) TW201729810A (enExample)
WO (1) WO2017072131A1 (enExample)
ZA (1) ZA201802183B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
AU2003272285A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び／又は治療剤
HUE039713T2 (hu) * 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére

Also Published As

Publication number Publication date
JP2018531288A (ja) 2018-10-25
US20170158671A1 (en) 2017-06-08
AU2016344627A1 (en) 2018-05-10
TW201729810A (zh) 2017-09-01
AU2020200840A1 (en) 2020-02-27
CL2018001092A1 (es) 2018-08-10
PH12018500822A1 (en) 2018-10-01
PE20181364A1 (es) 2018-08-27
ZA201802183B (en) 2019-02-27
HK1252050A1 (zh) 2019-05-10
RU2018119104A (ru) 2019-11-28
AU2016344627B9 (en) 2019-11-28
RU2018119104A3 (enExample) 2020-02-19
CA3001636A1 (en) 2017-05-04
AU2016344627B2 (en) 2019-11-07
EP3368528A1 (en) 2018-09-05
WO2017072131A1 (en) 2017-05-04
CO2018004323A2 (es) 2018-07-19
CN108602801A (zh) 2018-09-28
MX2018005140A (es) 2018-05-07
US20190135787A1 (en) 2019-05-09
ECSP18038867A (es) 2018-05-31
BR112018007765A2 (pt) 2018-10-23
SG11201802676QA (en) 2018-05-30
IL258813A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
AU2016344627B9 (en) Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine H4 receptor (H4) mediated diseases and conditions
CN103797010B (zh) 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
JP2018531288A6 (ja) ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法
JP6381016B2 (ja) 選択的ｃｄｋ４／６阻害剤の固体形態
CN113015521B (zh) 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物
EP3183252B1 (en) Oxalate salt of ruxolitinib
EP2918593B1 (en) Benfotiamine polymorphs, preparation method and use thereof
US12521396B2 (en) Pharmaceutical compositions comprising a MENIN inhibitor
TW202136263A (zh) 新穎 egfr 抑制劑
CN110167938A (zh) 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
TW201305143A (zh) 光學活性吡唑基胺基喹唑啉及其醫藥組合物及使用方法
KR20070085090A (ko) ５－ｈｔ１ａ 수용체 길항제의 약제학적 투여 형태 및조성물
TW202446392A (zh) 吡啶並吡唑衍生物的藥物組合物及其在醫藥上的應用
KR20250149691A (ko) 항섬유화 화합물의 고체 형태, 염 및 다형체
WO2020120606A1 (en) New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
CN102666528A (zh) 晶体cdc7 抑制剂盐
CN111225901A (zh) 用于治疗疼痛和与疼痛相关的病症的丙胺衍生物
WO2025147497A1 (en) Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same
HK40115093A (en) Parp1 inhibitors and uses thereof
JP2023533874A (ja) Ｐｎ６０４７の塩酸塩の多形体
HK40013317B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180523

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid